Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Celebrating 15 Years

PV0315_TarenGromPharmaVOICE has embarked upon a year of celebrating 15 years of raising the voices of tens=of thousands of industry leaders who have provided their time and energy to bringing forward their insights on the trends, challenges, and opportunities impacting an ever-evolving industry.

This month we are featuring a special forum — Reflections and Projections: the Past, Present, and Future —  with representatives spanning multiple functional areas and sectors of the industry, who provide their insights on the biggest change or changes they have seen in the industry in the past 15 years as well as where the industry is headed.

We also tapped a number of analysts to help shape this special forum. Prospectively, PwC says to take advantage of the next wave of opportunities, life-sciences companies need to adapt their business models. Cost-control efforts are leading to greater importance on value-based care (VBC). Also, comparative effectiveness research (CER) is becoming a major factor in a treatment’s market uptake. Life-sciences companies will need to develop capabilities to provide real-world evidence of positive patient outcomes to avoid exclusions and sales losses. Furthermore, the number and diversity of life-sciences customer segments suggest that one-size-fits-all approaches to understanding and addressing their needs as the industry explores new engagement models with an ever-evolving set of customers no longer works. The changing roles and influence of stakeholders along the care continuum call for a more cross-functional, collaborative customer model that effectively targets all critical decision-makers.

One of the biggest changes noted is the emergence of a very important decision maker: the patient. Patient centricity is impacting all aspects of the industry from R&D to commercialization. A part of this focus is the rare disease population. As Robin Robinson discusses in her feature article — Patients and Patient Organizations Power Rare Disease Therapies —  for the rare disease sector, the patient has always been front and center, championing for new therapies, looking for treatments, and demanding that the industry pay attention to their unmet needs. As we look forward to Rare Disease Day this February 29, we also look forward to the exciting innovations that are being driven by these passionate stakeholders who are looking for medicines to address the one in 10 Americans who has or will develop a rare disease; 95% of them are likely to have zero treatment options.

Unmet needs are also the hallmark of the CNS therapeutic category, specifically psychiatric illnesses. Denise Myshko talks to a variety of industry experts who discuss the many challenges involved in researching diseases that impact one in four American adults — 61.5 million people — who have been diagnosed with a mental health disorder.

We want to sincerely thank you, our readers, our contributors, our advertisers, and our many partners and supporters who have joined us on our journey and we look forward to many more years of being a forum for the industry.

Taren Grom, Editor


Their Word…
Denise MyPV0216_TheirWordshko
Managing Editor

There is a tremendous need for new medications for psychiatric illnesses.

Robin Robinson
Senior Editor

Patients in the rare disease space offer important influence over all phases of research and development, regulations, and commercialization.

Kim Ribbink
Features Editor

Japan is one of the stand-out global markets, second only to the U.S. in sales and with strong product pipelines.


Volume 15 • Number 2
Publisher    Lisa Banket
Editor    Taren Grom
Creative Director    Marah Walsh

Managing Editor
Denise Myshko

Senior Editor
Robin Robinson

Features Editor
Kim Ribbink

Design Associate
Ariel Medel

Director of Sales
Cathy Tracy

National Account Manager
Suzanne Besse

Webcast Network Producer
Daniel Limbach

Circulation Assistant
Kathy Deiuliis

Copyright 2015
by PharmaLinx LLC, Titusville, NJ
Printed in the U.S.A.
Volume Fifteen, Number Two

PharmaVoice (ISSN: 1932961X) is published monthly except joint issues in July/Aug. and Nov./Dec., by ­Pharma­­Linx LLC, P.O. Box 327, Titusville, NJ 08560. ­Periodicals postage paid at Titusville, NJ 08560 and additional mailing offices.

Postmaster: Send address changes to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345.

PharmaVoice Coverage and Distribution:
Domestic subscriptions are available at $190 for one year (10 issues). Foreign subscriptions: 10 issues US$360. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197.

Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless otherwise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. E-mail: tgrom@pharmavoice.com.

Change of address: Please allow six weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 292345, Kettering, OH 45429-0345. Call us at 800.607.4410 or FAX your change to 937.890.0221. E-mail: mwalsh@pharmavoice.com.

Important notice: The post office will not forward copies of this magazine. PharmaVoice is not responsible for replacing undelivered copies due to lack of or late notification of address change.

Advertising in PharmaVoice: To advertise in Pharma­­Voice please contact our Advertising ­Department at P.O. Box 327, Titusville, NJ 08560, or ­telephone us at 609.730.0196. E-mail: lbanket@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.